Biotechnology Company

News

23andMe, Biotechnology and Regeneron

Biotechnology company Regeneron buying 23andMe for $256 million

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said that it was looking to sell “substantially all of its assets” through a court-approved reorganization plan.

· 3d

Biotech company Regeneron to buy bankrupt 23andMe for $256M

· 3d

23andMe to Be Bought by Biotech Company for $256 Million

3don MSN

Major biotech company acquired after Chapter 11 bankruptcy

The acquisition marks a turning point for the company after months of financial uncertainty and data breach concerns.

Crain's Cleveland Business12h

Beachwood biotech company announces new CEO

The Beachwood-based company announced on Tuesday, May 20, that it has appointed Dr. David Llewellyn as its new CEO and as a ...

Northway Biotech Enters Manufacturing Agreement With Kaida BioPharma for Lead Oncology Program KAD101

Leveraging Northway Biotech’s 20+ years of CDMO expertise, Kaida BioPharma is advancing KAD101, a targeted therapy for ...

STAT19h

Biotech investor activism is on the rise

A recovery from this prolonged and painful market downturn will require a major attitude adjustment from biotech management ...

Labiotech.eu2d

Seven lung cancer companies advancing new treatments in 2025

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

Biotech Company 3SBio's Shares Surge After $6 Billion Licensing Deal With Pfizer

Chinese biotech company 3SBio's shares surged early Tuesday after its around US$6 billion licensing deal with Pfizer to develop, manufacture and commercialize a promising cancer drug. Shares were up ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results